INTRODUCTION: Endovascular coiling has remained an efficacious mechanism for aneurysm treatment. While continued biomechanical advancements in coil design have led to improved aneurysm embolization rates (1), aneurysm recanalization is estimated to remain between 21-33% (2, 3, 4). Post-occlusion, cerebral aneurysm sac growth has been identified as one of the driving components of aneurysm recurrence (2, 5). Recently, antiplatelet agents such as aspirin (ASA) have been shown to be significantly associated with decreased aneurysm growth and rupture (6, 7, 8). METHODS: All aneurysms treated by a single surgeon over 10 years (n = 2236) were screened for adherence to inclusion criteria. The primary endpoint was follow-up more than 12 months from the original intervention. Of 525 treated with coils only, 109 patients reported regular ASA use (defined as = 3x/ week, irrespective of dose). No significant demographic differences were identified between patients with regular ASA use and those without. While there were no significant differences in aneurysm size, location, or history of rupture, there was an increased presence of daughter sacs in patients without regular ASA. Rates of aneurysm recanalization, defined as a change of Raymond-Roy occlusion classification =1, were compared between ASA-treated and non-ASA-treated groups. RESULTS: Of the 109 coiled aneurysms with concomitant regular ASA use, only 9.2% underwent recanalization compared to 23.6% in patients without regular ASA use (P = 0.001, OR = 0.33, 95% CI = 0.15–0.66). Furthermore, when specifically considering cases of recanalization that only demonstrated sac growth, 5.5% occurred with regular ASA use compared to 18% without (P = 0.001, OR = 0.26, 95% CI = 0.09–0.63). CONCLUSIONS: ASA use significantly decreased the odds of post-coiling aneurysm sac growth and recanalization 12 months post-original intervention when compared to those without regular ASA use.
Read full abstract